Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.

Publication Type:

Journal Article


The Journal of infectious diseases, Volume 203, Issue 1, p.117-21 (2011)


2011, Acyclovir, Adult, Amino Acid Substitution, Antiviral Agents, Botswana, Center-Authored Paper, Drug Resistance, Viral, Female, Herpes Genitalis, Herpesvirus 2, Human, HIV Infections, HIV Reverse Transcriptase, HIV-1, Humans, KENYA, Male, Middle Aged, Molecular Sequence Data, Mutation, Missense, Peru, Point Mutation, Prospective Studies, Selection, Genetic, Sequence Analysis, DNA, United States, Vaccine and Infectious Disease Division, Valine


Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.